Medicines labeled for the same conditions
Alternatives to depemokimab
3 other medicines are given the same way (subcutaneous) and in the same FDA class as depemokimab or labeled mainly for the same use (asthma); the others include 1 interleukin-5 receptor alpha-directed cytolytic antibody, 1 interleukin-5 antagonist and 1 thymic stromal lymphopoietin blocker (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as depemokimab?
Asthma lists all 37 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Depemokimab | this medicine | none listed | n/a | No | No current entry |
| Benralizumabinterleukin-5 receptor alpha-directed cytolytic antibody | Asthma | none listed | n/a | No | No current entry |
| Mepolizumabinterleukin-5 antagonist | Asthma | none listed | n/a | No | No current entry |
| Tezepelumabthymic stromal lymphopoietin blocker | Asthma | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Depemokimab: the full record
- label, generics, price, shortages, recalls